Over the past 10-20 years researchers have enhanced our understanding of the metabolism and risk of drug interactions of numerous medications utilized by patients with pain conditions. Pain patients often are prescribed multiple medications that can inhibit or induce speci ccytochrome P450 (CYP450) enzymes. This review will focus on the effect of the CYP450 enzyme system metabolism on opioid agents codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone, as well as the potential effect of these opioids on the metabolism of other medications and vice versa.
Introduction

M
any patients with pain are prescribed multiple pharmacological interventions, often administered concurrently. Polypharmacy, a term that describes the use of multiple medications in patients [1] , can be a concern due to overlapping toxicities and increased risk of drug-drug interactions secondary to altered metabolism. Some data suggest that the risk of a drug-drug interaction increases with number of medications used, occur- ring in 13% of patients taking two medications and 82% of patients taking more than six medications [2] . It has been estimated that 75% of adverse reactions are related to interactions that increase or decrease the amount or action of the drug in the body by the presence of another drug or multiple drugs affecting its metabolism [3] .
Over the past 10-20 years, researchers have enhanced our understanding of the metabolism and risk of drug interactions of numerous medications utilized by patients with pain conditions. VVhile much of the research has focused on tricyclic antidepressants, selective serotonin reuptake inhibitor antidepressants, rst-generation anticonvulsants (e.g., carbamazepine and phenytoin), and methadone, recently there has been a heightReprint requertr to: Gregory L. Holmquist, PharmD, Group Health, Seattle, Washington, Palliative Care Strategies, Bothell, VVashington, 20918 35th Dr SE, Bothell, Washington 98021, USA. 5972; E-mail: rxrelief@aol.com. ©American Academy of Pain Medicine 1526-2375/O9/$15.00/S20 S20-S29 ened interest in the unique and speci c metabolism and thereby potential drug interaction risks of various opioid agents. An understanding of the metabolism of opioids will assist practitioners in avoiding clinically signi cantand dangerous interactions. This review will focus on the effect of the cytochrome P450 (CYP450) enzyme system metabolism on opioid agents such as codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone, as well as the potential effect of these opioids on the metabolism of other medications and vice versa.
CYP450 Enzyme System
All opioids are metabolized through two major enzyme systems, CYP450 and, to a lesser extent, by the UDP-glucuronosyltransferases (UGTS) with a speci caf nityfor the UGTZB7 isozyme. The UGTs are a secondary metabolizing system responsible for the formation of glucuronidcs and have a major role in the metabolism of hydromorphone, morphine, and oxymorphone. The CYP450 system is of major signi cance in the metabolism of codeine, fentanyl, methadone, oxycodone, and oxymorphone. As will be discussed later, due to genetic variation in CYP450 and to the potential for drug interactions, these later ve agents have signi cantrisks for wide serum level variation.
CYP450 enzymes are present in many tissues of the body, including the endoplasmic reticula in doi:10.1111/j.1526-4637.2009.00596.x hepatocytes, intestinal mucosa, lungs, brain, and kidney [4] . efficacy of patient response to analgesia from morphine [39, 40] .
Hydromorphone, Morphine, Oxymorphone, and the UGT System
The chiefmetnbolic patlwmys, metabolites and the potential role of Codeine, fentanyl, hydrocodone, hydromorphone, methadone, oxycodone, and oxymorphone as substrates, inhibitors, or inducers of CYP450 are outlined in Table 3 . As noted, hydromorphone, morphine and 0X_VI11()1'ph()I1€ are not metabolized by CYP450 enzymes to any great extent; therefore, inhibition/induction or genetic polymorphisms of CYP45O enzymes should have little to no effect on the metabolism or clearance of these agents. The chief pathvvay of these three agents is the UGT 2B7 metabolic piitliway that in the biotransformation of codeine into the active form morphine [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [38, 62] . Induction of the metabolism of methadone poses the risk ofinducing withdrawal reactions and increased levels of pain. 
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